Literature DB >> 31160135

Waiting time to surgery and pancreatic cancer survival: A nationwide population-based cohort study.

Jakob Kirkegård1, Frank Viborg Mortensen2, Carsten Palnæs Hansen3, Michael Bau Mortensen4, Mogens Sall5, Claus Fristrup6.   

Abstract

INTRODUCTION: The effect of waiting time to surgery on survival in pancreatic cancer patients is unclear. We examined this association in a nationwide population-based cohort study.
MATERIALS AND METHODS: A nationwide population-based cohort study of all patients undergoing surgery for pancreatic cancer (resection or a palliative procedure) registered in the Danish Pancreatic Cancer Database from May 2011 to May 2016. We defined waiting time to surgery in two ways: 1) from the date of entry into the National Cancer Pathway to the date of surgery and 2) from the date of the last preoperative computed tomography (CT) or positron emission tomography (PET-CT) scan to the date of surgery. Waiting time was grouped into three groups: <28 days (<4 weeks), 28-55 days (4-8 weeks), and ≥56 days (≥8 weeks). We calculated median survival with associated 95% confidence intervals (CIs) for patients undergoing resection and for patients undergoing a palliative procedure.
RESULTS: We included 873 patients. Mean age was 67 years (range: 35-86 years). Resection was performed in 701 patients (80%); the remaining 172 patients (20%) underwent an explorative laparotomy or palliative surgery. 652 patients (75%) had a registration in the National Cancer Pathway (median waiting time: 31 days, and 818 patients (94%) had registration of a preoperative CT or PET-CT scan (median waiting time: 32 days). We saw similar resection rates (∼80%) and median survival (∼22 months) in all thee groups.
CONCLUSION: In this study, waiting time to surgery did not affect survival in patients undergoing surgery for pancreatic cancer.
Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  General surgery; Pancreatic neoplasms; Prognosis; Survival

Mesh:

Year:  2019        PMID: 31160135     DOI: 10.1016/j.ejso.2019.05.029

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

1.  Does Preoperative Waiting Time Affect the Short-Term Outcomes and Prognosis of Colorectal Cancer Patients? A Retrospective Study from the West of China.

Authors:  Xiao-Yu Liu; Zi-Wei Li; Bing Kang; Yu-Xi Cheng; Wei Tao; Bin Zhang; Hua Zhang; Zheng-Qiang Wei; Dong Peng
Journal:  Can J Gastroenterol Hepatol       Date:  2022-04-30

2.  Gastrointestinal Malignancies and the COVID-19 Pandemic: Evidence-Based Triage to Surgery.

Authors:  Scott C Fligor; Sophie Wang; Benjamin G Allar; Savas T Tsikis; Ana Sofia Ore; Ashlyn E Whitlock; Rodrigo Calvillo-Ortiz; Kevin R Arndt; Sidhu P Gangadharan; Mark P Callery
Journal:  J Gastrointest Surg       Date:  2020-06-30       Impact factor: 3.452

3.  Minimizing Population Health Loss in Times of Scarce Surgical Capacity During the Coronavirus Disease 2019 Crisis and Beyond: A Modeling Study.

Authors:  Benjamin Gravesteijn; Eline Krijkamp; Jan Busschbach; Geert Geleijnse; Isabel Retel Helmrich; Sophie Bruinsma; Céline van Lint; Ernest van Veen; Ewout Steyerberg; Kees Verhoef; Jan van Saase; Hester Lingsma; Rob Baatenburg de Jong
Journal:  Value Health       Date:  2021-03-05       Impact factor: 5.725

4.  Mortality Increases When Radical Nephrectomy is Delayed More Than 60 Days for T3 Renal Cell Carcinoma.

Authors:  Fangzheng Zhao; Xiaoxiao Liu; Chu Zhang; Haitao Zhu; Nienie Qi
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

5.  Dynamic monitoring revealed a slightly prolonged waiting time for total gastrectomy during the COVID-19 pandemic without increasing the short-term complications.

Authors:  Xiaohao Zheng; Shikang Ding; Ming Wu; Chunyang Sun; Yunzi Wu; Shenghui Wang; Yongxing Du; Lin Yang; Liyan Xue; Bingzhi Wang; Chengfeng Wang; Wei Cui; Yibin Xie
Journal:  Front Oncol       Date:  2022-08-31       Impact factor: 5.738

Review 6.  Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine.

Authors:  R Casolino; C Braconi; G Malleo; S Paiella; C Bassi; M Milella; S B Dreyer; F E M Froeling; D K Chang; A V Biankin; T Golan
Journal:  Ann Oncol       Date:  2020-11-26       Impact factor: 32.976

7.  First Course of treatment and Prognosis of Exocrine Pancreatic Cancer in Korea from 2006 to 2017.

Authors:  Mee Joo Kang; Jiwon Lim; Sung-Sik Han; Hyeong Min Park; Sang-Jae Park; Young-Joo Won; Sun-Whe Kim
Journal:  Cancer Res Treat       Date:  2021-05-21       Impact factor: 4.679

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.